Skip to main content

Profile: Kevin Garey

Kevin Garey
Kevin W. Garey, Pharm.D., M.S., FASHP
Chair, Department of Pharmacy Practice and Translational Research
Professor of Pharmacy Practice
Health 2
University of Houston College of Pharmacy
4849 Calhoun, Room 4039
Houston, TX 77204-5039

832-842-8386
KGarey@uh.edu

Education

Bachelor of Science in Pharmacy, 1991-95, Dalhousie University, Halifax, Nova Scotia

Doctorate of Pharmacy, 1995-97, University at Buffalo, Buffalo, NY

M.S. in Biometry, 2007, University of Texas School of Public Health, Houston, TX

Research Interests

  • Infectious disease epidemiology
  • Post-operative infections
  • Biofilm activity of antimicrobials
  • Clostridium difficile infection

Awards & Honors

  • Rho Chi Bergy Lecture Recipient, West Virginia University Morgantown, WV, 2017
  • Top 10 Papers in Mycology, ICAAC 2014, Washington, D.C. ("T2 Magnetic Resonance Assay for the Rapid Diagnosis of Candidemia in Whole Blood: A Clinical Trial," Clin Infect Dis. 2015 Mar 15;60(6):892-9. doi: 10.1093/cid/ciu959. Epub 2015 Jan 12. PMID: 25586686)
  • Faculty Leadership Award, University of Houston Chapter of Phi Lambda Sigma Pharmacy Leadership Society, 2013
  • Impact Paper of the Year, Society of Infectious Diseases Pharmacists, 2012 ("A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection." J Antimicrob Chemother. 2011 Dec;66(12):2850-5. PubMed abstract)
  • Fellow, American Society of Health-System Pharmacists, 2012
  • Faculty Research Excellence Award, UH College of Pharmacy, 2007
  • Society of Infectious Diseases Pharmacists Impact Paper in Infectious Diseases, 2007
  • Literature Award in Drug Therapy, American Society of Health-System Pharmacists Research & Education Foundation, 2007
  • Pharmacotherapy Paper of the Year Award, Society of Infectious Diseases Pharmacists, 2007
  • UH College of Pharmacy Rho Chi Teacher Excellence Award, 2003
  • UH College of Pharmacy Faculty Teaching Excellence Award, 2003
  • Rho Chi member, 2003
  • Who's Who in Medicine and Healthcare, 2003

Courses

  • Pharm.D.: Lecturer for Drug Therapeutics, Pharmacodynamics, Research Methods, Infectious Disease elective (course coordinator), OTC Agents, and Literature Evaluation
  • Graduate Programs: Lecturer for Research Seminar in Pharmacy Administration, Seminar Series in Healthcare Leadership (course coordinator), Residency Teaching Certificate Program, and Introduction to Health System Management (course coordinator)

Selected Publications (since 2015)

Google Scholar

Kiles TM, Zhao AV, Wanat MA, Garey KW, Hatfield CL. Knowledge and self-perception comparisons between students with and without prior technician experience in community pharmacy lab courses. Curr Pharm Teach Learn. 2021 Mar;13(3):279-287. doi: 10.1016/j.cptl.2020.10.004. Epub 2020 Nov 27. PMID: 33641739

Kiles TM, Garey KW, Wanat MA, Pitman P. A survey to assess experiences and social support of underrepresented minority doctor of pharmacy students. Curr Pharm Teach Learn. 2021 Mar;13(3):245-254. doi: 10.1016/j.cptl.2020.10.015. Epub 2020 Nov 24. PMID: 33641734

Bassères E, Endres BT, Montes-Bravo N, Pérez-Soto N, Rashid T, Lancaster C, Begum K, Alam MJ, Paredes-Sabja D, Garey KW. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores. Anaerobe. 2021 Feb 25;69:102352. doi: 10.1016/j.anaerobe.2021.102352. Online ahead of print. PMID: 33640461

Asias-Dinh BD, Garey KW. Factors associated with abnormal glucose readings in a pharmacy-led community health fair using the ADA risk assessment tool. J Am Pharm Assoc (2003). 2021 Mar-Apr;61(2):174-180. doi: 10.1016/j.japh.2020.11.002. Epub 2020 Nov 27. PMID: 33257174

Carlson TJ, Gonzales-Luna AJ, Garey KW. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol. 2021 Jan;37(1):30-36. doi: 10.1097/MOG.0000000000000696. PMID: 33229860

Engevik MA, Danhof HA, Auchtung J, Endres BT, Ruan W, Bassères E, Engevik AC, Wu Q, Nicholson M, Luna RA, Garey KW, Crawford SE, Estes MK, Lux R, Yacyshyn MB, Yacyshyn B, Savidge T, Britton RA, Versalovic J. Fusobacteriumnucleatum Adheres to Clostridioides difficile via the RadD Adhesin to Enhance Biofilm Formation in Intestinal Mucus. Gastroenterology. 2021 Mar;160(4):1301-1314.e8. doi: 10.1053/j.gastro.2020.11.034. Epub 2020 Nov 21. PMID: 33227279

Carlson TJ, Gonzales-Luna AJ, Nebo K, Chan HY, Tran NT, Antony S, Lancaster C, Alam MJ, Begum K, Garey KW. Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection. Open Forum Infect Dis. 2020 Oct 7;7(11):ofaa476. doi: 10.1093/ofid/ofaa476. eCollection 2020 Nov. PMID: 33209956 Free PMC article.

Sprague R, Warny K, Pollock N, Daugherty K, Lin Q, Xu H, Cuddemi C, Barrett C, Chen X, Banz A, Lantz A, Garey KW, Gonzales-Luna AJ, Alonso CD, Galvez JAV, Kelly CP. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2020 Nov 8. doi: 10.1007/s10620-020-06683-8. Online ahead of print. PMID: 33164145

Thabit AK, Shea KM, Guzman OE, Garey KW. Antibiotic utilization within 18 community hospitals in the United States: A 5-year analysis. Pharmacoepidemiol Drug Saf. 2021 Apr;30(4):403-408. doi: 10.1002/pds.5156. Epub 2020 Nov 20. PMID: 33094502

Garey KW, Begum K, Lancaster C, Gonzales-Luna A, Bui D, Mercier J, Seng Yue C, Ducharme MP, Hu M, Vince B, Silverman MH, Alam MJ, Kankam M. A randomized, double-blind, placebo-controlled, single and multiple ascending dose Phase 1 study to determine the safety, pharmacokinetics and food and faecal microbiome effects of ibezapolstat administered orally to healthy subjects. J Antimicrob Chemother. 2020 Dec 1;75(12):3635-3643. doi: 10.1093/jac/dkaa364. PMID: 32892222

Crutchley RD, Jacobs DM, Gathe J, Mayberry C, Bulayeva N, Rosenblatt KP, Garey KW. Vitamin D Assessment Over 48 Weeks in Treatment-Naive HIV Individuals Starting Lopinavir/Ritonavir Monotherapy. Curr HIV Res. 2021;19(1):61-72. doi: 10.2174/1570162X18666200827115615. PMID: 32860360

Yepez Guevara EA, Aitken SL, Olvera AV, Carlin L, Fernandes KE, Bhatti MM, Garey KW, Adachi J, Okhuysen PC. Clostridioides difficile infection in cancer and immunocompromised patients: Relevance of a two-step diagnostic algorithm and infecting ribotypes on clinical outcomes. Clin Infect Dis. 2020 Aug 17:ciaa1184. doi: 10.1093/cid/ciaa1184. Online ahead of print. PMID: 32803229

ngevik MA, Luck B, Visuthranukul C, Ihekweazu FD, Engevik AC, Shi Z, Danhof HA, Chang-Graham AL, Hall A, Endres BT, Haidacher SJ, Horvath TD, Haag AM, Devaraj S, Garey KW, Britton RA, Hyser JM, Shroyer NF, Versalovic J. Human-Derived Bifidobacterium dentium Modulates the Mammalian Serotonergic System and Gut-Brain Axis. E Cell Mol Gastroenterol Hepatol. 2021;11(1):221-248. doi: 10.1016/j.jcmgh.2020.08.002. Epub 2020 Aug 12. PMID: 32795610

Bassères E, Begum K, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Miranda J, Rashid T, Alam MJ, Eyre DW, Wilcox MH, Garey KW. In vitro activity of eravacycline against common ribotypes of Clostridioides difficile. J Antimicrob Chemother. 2020 Oct 1;75(10):2879-2884. doi: 10.1093/jac/dkaa289. PMID: 32719870

Skoglund E, Fernandez J, Sherer JT, Coyle EA, Garey KW, Fleming ML, Sofjan AK. Using the Theory of Planned Behavior to Evaluate Factors That Influence PharmD Students' Intention to Attend Lectures. Am J Pharm Educ. 2020 May;84(5):7550. doi: 10.5688/ajpe7550. PMID: 32577029

Dubberke ER, Gerding DN, Kelly CP, Garey KW, Rahav G, Mosley A, Tipping R, Dorr MB. Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection. Open Forum Infect Dis. 2020 Jun 2;7(6):ofaa157. doi: 10.1093/ofid/ofaa157. eCollection 2020 Jun. PMID: 32523972

Begum K, Bassères E, Miranda J, Lancaster C, Gonzales-Luna AJ, Carlson TJ, Rashid T, Eyre DW, Wilcox MH, Alam MJ, Garey KW. In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile. Antimicrob Agents Chemother. 2020 Jul 22;64(8):e00522-20. doi: 10.1128/AAC.00522-20. Print 2020 Jul 22. PMID: 32513796

Hengel RL, Ritter TE, Nathan RV, Van Anglen LJ, Schroeder CP, Dillon RJ, Marcella SW, Garey KW. Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study. Open Forum Infect Dis. 2020 Mar 19;7(4):ofaa097. doi: 10.1093/ofid/ofaa097. eCollection 2020 Apr. PMID: 32363211

Engevik MA, Danhof HA, Chang-Graham AL, Spinler JK, Engevik KA, Herrmann B, Endres BT, Garey KW, Hyser JM, Britton RA, Versalovic J. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020 May 1;318(5):G870-G888. doi: 10.1152/ajpgi.00045.2020. Epub 2020 Mar 30. PMID: 32223302

Alosaimy S, Jorgensen SCJ, Lagnf AM, Melvin S, Mynatt RP, Carlson TJ, Garey KW, Allen D, Venugopalan V, Veve M, Athans V, Saw S, Yost CN, Davis SL, Rybak MJ. Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections. Open Forum Infect Dis. 2020 Feb 19;7(3):ofaa051. doi: 10.1093/ofid/ofaa051. eCollection 2020 Mar. PMID: 32161775

Gonzales-Luna AJ, Carlson TJ, Dotson KM, Poblete K, Costa G, Miranda J, Lancaster C, Walk ST, Tupy S, Begum K, Alam MJ, Garey KW. PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255. Emerg Microbes Infect. 2020 Feb 10;9(1):341-347. doi: 10.1080/22221751.2020.1721335. eCollection 2020. PMID: 32037964

Carlson TJ, Blasingame D, Gonzales-Luna AJ, Alnezary F, Garey KW. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020 Apr;62:102142. doi: 10.1016/j.anaerobe.2019.102142. Epub 2019 Dec 19. PMID: 32007682

Carlson TJ, Endres BT, Le Pham J, Gonzales-Luna AJ, Alnezary FS, Nebo K, Miranda J, Lancaster C, Bassères E, Begum K, Alam MJ, Reveles KR, Garey KW. Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection. Open Forum Infect Dis. 2020 Jan 4;7(1):ofz552. doi: 10.1093/ofid/ofz552. eCollection 2020 Jan. PMID: 31993458

Doern GV, Carroll KC, Diekema DJ, Garey KW, Rupp ME, Weinstein MP, Sexton DJ. Practical Guidance for Clinical Microbiology Laboratories: A Comprehensive Update on the Problem of Blood Culture Contamination and a Discussion of Methods for Addressing the Problem. Clin Microbiol Rev. 2019 Oct 30;33(1):e00009-19. doi: 10.1128/CMR.00009-19. Print 2019 Dec 18. PMID: 31666280. Review.

Spinler JK, Gonzales-Luna AJ, Raza S, Runge JK, Luna RA, Savidge TC, Garey KW. Complete Genome Sequence of Clostridioides difficile Ribotype 255 Strain Mta-79, Assembled Using Oxford Nanopore and Illumina Sequencing. Microbiol Resour Announc. 2019 Oct 17;8(42):e00935-19. doi: 10.1128/MRA.00935-19. PMID: 31624167

Rashid T, Haghighi F, Hasan I, Bassères E, Alam MJ, Sharma SV, Lai D, DuPont HL, Garey KW.  Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01031-19. doi: 10.1128/AAC.01031-19. Print 2019 Dec 20. PMID: 31611365

Garey KW. Perils, Pitfalls, and Promise of Primary Prophylaxis for Clostridioides difficile Infection. Clin Infect Dis. 2020 Aug 22;71(5):1140-1141. doi: 10.1093/cid/ciz970. PMID: 31560048

Vickers RJ, Bassetti M, Clancy CJ, Garey KW, Greenberg DE, Nguyen MH, Roblin D, Tillotson GS, Wilcox MH. Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiol. 2019 Oct;14:1331-1341. doi: 10.2217/fmb-2019-0227. Epub 2019 Sep 17. PMID: 31526186

WJ Shen, A Deshpande, KE Hevener, BT Endres, KW Garey, K Palmer, JG Hurdle. Constitutive Expression of the Cryptic vanGCd Operon Promotes Vancomycin Resistance in Clostridioides difficile Clinical Isolates, J Antimicrob Chemother. 2020 Apr 1;75(4):859-867. doi: 10.1093/jac/dkz513. PMID: 31873741

VH Tam, D Cohen, K Ledesma, B Guillory, K Chan, KW Garey. Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. Antimicrob Agents Chemother. 2020 Feb 21;64(3):e02090-19. doi: 10.1128/AAC.02090-19. Print 2020 Feb 21. PMID: 31871078

Shelburne S, Dib R, Endres BT, Reitzel R, Li X, Kalia A, Sahasrabhojane P, Chaftari AM, Hachem R, Vargas-Cruz N, Jiang Y, Garey KW, Fowler V, Holland T, Gu J, Miller M, Sakurai A, Arias C, Aitken S, Greenberg D, Kim, J, Raad I. Whole genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteremia is caused by a limited number of closely related sequence types. Clin Microbiol Infect 2019, Oct 19. pii: S1198-743X(19)30535-X. doi: 10.1016/j.cmi.2019.10.008. PMID 31639470

T Rashid, F Haghighi, I Hasan, E Bassères, MJ Alam, SV Sharma, D Lai, HL DuPont, KW Garey. Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01031-19. doi: 10.1128/AAC.01031-19. Print 2019 Dec 20. PMID: 31611365

AK Sofjan, MA Islam, K Halder, ND Kabir, AA Saleh, J Miranda, C Lancaster, K Begum, MJ Alam, KW Garey. Molecular epidemiology of Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe 2019, Jul 26:102081. doi: 10.1016/j.anaerobe.2019.102081. PMID: 31356958

Q Lin, NR Pollock, A Banz, A Lantz, H Xu, L Gu, DN Gerding, KW Garey, AJ Gonzales-Luna, M Zhao, L Song, DC Duffy, CP Kelly, X Chen. Toxin A-predominant Pathogenic C. difficile: A Novel Clinical Phenotype. Clin Infect Dis 2019 Aug 11. pii: ciz727. doi: 10.1093/cid/ciz727. PMID: 31400280

K Rainha, RF Ferreira, CN Trindade, LG Carneiro, B Penna, BT Endres, K Begum, MJ Alam, KW Garey, R Maria, C Domingues, E Ferreira. Characterization of Clostridioides difficile ribotypes in domestic dogs in Rio de Janeiro, Brazil. Anaerobe 2019, Jun 17. pii: S1075-9964(19)30104-0. doi: 10.1016/j.anaerobe.2019.06.007. PMID:31220606

MJ Alam, J McPherson, J Miranda, A Thrall, V Ngo, R Kessinger, K Begum, M Marin, KW Garey. Molecular epidemiology of Clostridioides difficile in domestic dogs and zoo animals. Anaerobe 2019, Jun 14. pii: S1075-9964(19)30102-7. doi: 10.1016/j.anaerobe.2019.06.005. PMID: 31207298

MA Engevik, B Luk, AL Chang-Graham, A Hall, B Herrmann, W Ruan, BT Endres, Z Shi, KW Garey, J Hyser, J Versalovic. Bifidobacterium dentium fortifies the intestinal mucus layer via autophagy and calcium signaling pathways. MBio 2019, Jun 18;10(3). pii: e01087-19. doi: 10.1128/mBio.01087-19. PMID: 31213556

BT Endres, K Begum, H Sun, ST Walk, A Memariani, C Lancaster, AJ Gonzales-Luna, KM Dotson, E Bassères, C Offiong, S Tupy, K Kuper, E Septimus, R Arafat, MJ Alam, Z Zhao, JG Hurdle, TC Savidge, KW Garey. Early emergence of epidemic Clostridioides difficile ribotype 027 lineages in the US: implications for fluoroquinolone use. Open Forum Infect Dis 2019;6(2)ofz013. PMID: 30793006

SB Bhakta, AC Colavecchia, L Haines, D Varkey, KW Garey. A Systematic Approach to Optimize Health-System Electronic Health Record Medication Alerts. Amer J Health-syst Pharm 2019 Apr 8;76(8):530-536. doi: 10.1093/ajhp/zxz012. PMID:31361861

KL Yee, HJ Kleijn, T Kerbusch, RP Matthews, MB Dorr, KW Garey, RE Wrishko. Population pharmacokinetics and pharmacodynamics of bezlotoxumab in adults with primary and recurrent Clostridium difficile infection. Antimicrob Agents Chemother 2018 Nov 19. pii: AAC.01971-18. doi: 10.1128/AAC.01971-18. PMID:30455246

E Skoglund, C Dempsey, H Chen, KW Garey. Estimated clinical and economic impact through use of a novel blood collection device to reduce blood culture contamination in the emergency department: A cost-benefit analysis. J Clin Microbiol. 2018 Oct 24. pii: JCM.01015-18. doi: 10.1128/JCM.01015-18. PMID: 30355758

KR Reveles, KM Dotson, A Gonzales-Luna, D Surati, BT Endres, MJ Alam, KW Garey. Clostridioides (formerly Clostridium) difficile infection during hospitalization increases the likelihood of non-home patient discharge. Clin Infect Dis. 2018 Sep 11. doi: 10.1093/cid/ciy782. PMID: 30204878

ND Beyda, J Amadio, JR Rodriguez, K Malinowski, KW Garey, A Wanger, L Ostrosky-Zeichner. In vitro evaluation of BacT/Alert FA blood Culture bottles and T2Candida assay for the detection of Candida in the presence of antifungals. J Clin Microbiol 2018 Jun 13. pii: JCM.00471-18. doi: 10.1128/JCM.00471-18. PMID:29898999

McDonald LC, Johnson S, Bakken JS, Garey KW, Kelly C, Gerding DN. Reply to Fabre et. al. Clin Infect Dis. 2018 May 31. doi: 10.1093/cid/ciy475. PMID: 29860268

BT Endres, KM Dotson, K Poblete, J McPherson, C Lancaster, E Bassères, A Memariani, S Arnold, S Tupy, C Carlsen, B Morehead, S Anyatonwu, C Cook, K Begum, MJ Alam, KW Garey. Environmental transmission of Clostridioides difficile ribotype 027 at a long-term care facility; an outbreak investigation guided by whole genome sequencing. Infect Control Hosp Epidemiol 2018 Nov;39(11):1322-1329. PMID:30253813

Davis ML, Sparrow HG, Ikwuagwu JO, Musick WK, Garey KW, Perez KK. A multi-center derivation and validation of a simple predictive index for healthcare-associated Clostridium difficile infection. Clin Microbiol Infect 2018 Nov;24(11):1190-1194. PMID:29454848

AK Sofjan, B Casey, BA Xu, J Amadio, A Restrepo, MJ Alam, KW Garey. Accelerate PhenoTest™ BC Kit vs. Conventional Methods for Gram-positive Bloodstream Infections: Diagnostic Performance and implications for Antimicrobial Stewardship. Ann Pharmacother 2018 Aug;52(8):754-762. PMID: 29557208

AK Sofjan, A Mitchell, DN Shah, T Nguyen, M Sim, A Trojcak, ND Beyda, KW Garey. Rezafungin (CD101), a next generation echinocandin. A systematic literature review and assessment of possible place in therapy. J Glob Antimicrob Resist 2018 Sep;14:58-64. PMID:29486356

JN Addo Smith, R Yau, HP Russo, K Putney, A Restrepo, KW Garey, AK Sofjan. Bacteremia in patients with liver cirrhosis: prevalence and predictors of multidrug resistant organisms. J Clin Gastroenterol 2018 Aug;52(7):648-654. PMID: 29176351

Sofjan AK, Musgrove RJ, Beyda ND, Russo HP, Lasco TM, Yau R, Restrepo A, Garey KW. Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary center in the United States. J Glob Antimicrob Resist. 2018 May 26;15:41-47. PMID: 29842975

KM Dotson, SL Aitken, A Sofjan, DN Shah, R Aparasu, and KW Garey. Outcomes associated with Clostridium difficile infection in patients with chronic liver disease. Epidemiol Infect 2018; 146(9):1101-1105. PMID 29739486

S Pattharachayakul, P Wongpoowarak, W Santimaleeworagun, P Tansakul, P Chayakul, and KW Garey. BLAoxa-23-like presence and 29 KDA porin loss in carbapenem resistant Acinetobacter baumannii clinical isolates in Thailand. Southeast Asian J Trop Med Public Health 2018;49(3):401-8

CJ Clancy, PG Pappas, J Vazquez, M Judson, DP Kontoyiannis, GR Thompson, KW Garey, A Reboli, R Greenberg, S Apewokin, M Lyons, L Ostrosky-Zeichner, A Wu, E Tobin, MH Nguyen, AM Caliendo. Detecting Infections Rapidly and Easily for Candidemia Trial-2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. Clin Infect Dis. 2018 2018 May 17;66(11):1678-1686. PMID:29438475

LC McDonald, DN Gerding, S Johnson, JS. Bakken, KC Carroll, SE Coffin, ER Dubberke, KW Garey, CV Gould, C Kelly, Loo, JS Sammons, TJ Sandora, MH Wilcox. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987-94. PMID: 29462280

Bhakta SB, Colavecchia AC, Coffey W, Curlee DR, Garey KW. Implementation and evaluation of a sterile compounding robot in a satellite oncology pharmacy. Am J Health Syst Pharm. 2018 Jun 1;75(11 Supplement 2):S51-S57. PMID:29802179

T Rashid, K Poblete, J Amadio, I Hasan, K Begum, MJ Alam, KW Garey. Evaluation of a shoe sole UVC device to reduce pathogen colonization on floors, surfaces, and patients. J Hosp Infect. 2018;98(1):96-101. PMID: 29066141

Yu H, Chen K, Sun Y, Carter M, Garey KW, Savidge TC, Devaraj S, Tessier ME, von Rosenvinge EC, Kelly CP, Pasetti MF, Feng H. Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00037-17. doi: 10.1128/CVI.00037-17. PMID:28592627

Vickers RJ, Tillotson G, Goldstein EJ, Citron DM, Garey KW, Wilcox MH. Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 May 30. pii: S0924-8579(16)30117-0. doi: 10.1016/j.ijantimicag.2016.04.026. Review. PMID: 27283730

Shah DN, Aitken SL, Barragan LF, Bozorgui S, Goddu S, Navarro ME, Xie Y, DuPont HL, Garey KW. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. J Hosp Infect. 2016 Jul;93(3):286-9. doi: 10.1016/j.jhin.2016.04.004. PMID: 27209056

Jacobs DM, Kuper K, Septimus E, Arafat R, Garey KW. Assessment of Antimicrobial Stewardship Activities in a Large Metropolitan Area. J Pharm Pract. 2016 Jun;29(3):188-93. doi: 10.1177/0897190014549842. PMID: 25312262

Gorbach C, Blanton L, Lukawski B, Varkey AC, Pitman P, Garey KW. Benchmarking and medication error rates. Am J Health Syst Pharm. 2016 Jun 1;73(11):746. doi: 10.2146/ajhp150961. PMID: 27208057

Endres BT, Bassères E, Memariani A, Chang L, Alam MJ, Vickers RJ, Kakadiaris IA, Garey KW. A novel method for imaging the pharmacological effects of antibiotic treatment on Clostridium difficile. Anaerobe. 2016 Apr 21;40:10-14. doi: 10.1016/j.anaerobe.2016.04.013. PMID: 27108094

Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12;15:22. doi: 10.1186/s12941-016-0140-6. PMID: 27071986

Endres BT, Bassères E, Khaleduzzaman M, Alam MJ, Chesnel L, Garey KW. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 May 23;60(6):3519-23. doi: 10.1128/AAC.00211-16. PMID: 27021314

Bassères E, Endres BT, Khaleduzzaman M, Miraftabi F, Alam MJ, Vickers RJ, Garey KW. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May;71(5):1245-51. doi: 10.1093/jac/dkv498. PMID: 26895772

Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, Barbut F, Shah DN, DuPont HL. Development and Validation of a Clostridium difficile Health-related Quality-of-Life Questionnaire. J Clin Gastroenterol. 2016 Sep;50(8):631-7. doi: 10.1097/MCG.0000000000000473. PMID: 26796081

Philip A, Desai A, Nguyen PA, Birney P, Colavecchia A, Karralli R, Smith L, Lorimer D, Burgess G, Munch K, Daniel N, Lionetti J, Garey KW. Evaluating pharmacy leader development through the seven action logics. Am J Health Syst Pharm. 2016 Jan 15;73(2):82-5. doi: 10.2146/ajhp150162. PMID: 26721538

Sayles C, Hickerson SC, Bhat RR, Hall J, Garey KW, Trivedi MV. Oral Glutamine in Preventing Treatment-Related Mucositis in Adult Patients With Cancer: A Systematic Review. Nutr Clin Pract. 2016 Apr;31(2):171-9. doi: 10.1177/0884533615611857. Review. PMID: 26507188

Gorbach C, Blanton L, Lukawski BA, Varkey AC, Pitman EP, Garey KW. Frequency of and risk factors for medication errors by pharmacists during order verification in a tertiary care medical center. Am J Health Syst Pharm. 2015 Sep 1;72(17):1471-4. doi: 10.2146/ajhp140673 PMID: 26294240

Aitken SL, Alam MJ, Khaleduzzaman M, Walk ST, Musick WL, Pham VP, Christensen JL, Atmar RL, Xie Y, Garey KW. In the Endemic Setting, Clostridium difficile Ribotype 027 Is Virulent But Not Hypervirulent. Infect Control Hosp Epidemiol. 2015 Nov;36(11):1318-23. doi: 10.1017/ice.2015.187. Epub 2015 Aug 20. Erratum in: Infect Control Hosp Epidemiol. 2016 Jan;37(1):124. Khaleduzzuman, Mohammed [corrected to Khaleduzzaman, Mohammed]. PMID: 26288985

Pham VP, Luce AM, Ruppelt SC, Wei W, Aitken SL, Musick WL, Roux RK, Garey KW. Age-Stratified Treatment Response Rates in Hospitalized Patients with Clostridium difficile Infection Treated with Metronidazole. Antimicrob Agents Chemother. 2015 Oct;59(10):6113-6. doi: 10.1128/AAC.00816-15. PMID: 26195522

Blee J, Roux RK, Gautreaux S, Sherer JT, Garey KW. Dispensing inhalers to patients with chronic obstructive pulmonary disease on hospital discharge: Effects on prescription filling and readmission. Am J Health Syst Pharm. 2015 Jul 15;72(14):1204-8. doi: 10.2146/ajhp140621. PMID: 26150570

Beyda ND, Liao G, Endres BT, Lewis RE, Garey KW. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrob Agents Chemother. 2015 Sep;59(9):5405-12. doi: 10.1128/AAC.00624-15. PMID: 26100700

Philip A, Gessner-Wharton M, Birney P, Blee J, Desai A, Gorbach C, Karralli R, Lorimer D, Munch K, Nweke G, Parekh S, Puebla M, Cox R, Pitman EP, Garey KW. Pharmacy Practice Model Initiative task force report: Improving participation in a survey on hospital pharmacy practices in Texas. Am J Health Syst Pharm. 2015 Jun 15;72(12):1053-7. doi: 10.2146/ajhp140471. PMID: 26025997

Nesher L, Hadi CM, Salazar L, Wootton SH, Garey KW, Lasco T, Luce AM, Hasbun R. Epidemiology of meningitis with a negative CSF Gram stain: under-utilization of available diagnostic tests. Epidemiol Infect. 2016 Jan;144(1):189-97. doi: 10.1017/S0950268815000850. PMID: 25989841

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. Reply to Bauer and Goff. Clin Infect Dis. 2015 Aug 1;61(3):487-8. doi: 10.1093/cid/civ357. PMID: 25944341

Kilic A, Alam MJ, Tisdel NL, Shah DN, Yapar M, Lasco TM, Garey KW. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med. 2015 May;35(3):306-13. doi: 10.3343/alm.2015.35.3.306. PMID: 25932438

Na X, Martin AJ, Sethi S, Kyne L, Garey KW, Flores SW, Hu M, Shah DN, Shields K, Leffler DA, Kelly CP. A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection. PLoS One. 2015 Apr 23;10(4):e0123405. doi: 10.1371/journal.pone.0123405. eCollection 2015. PMID: 25906284

Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow LL, Aronoff DM, Garey KW, Savidge TC, von Rosenvinge EC, Kelly CP, Feng H. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015 Apr 17;10(4):e0124235. doi: 10.1371/journal.pone.0124235. eCollection 2015. PMID: 25885671

Philip A, Green M, Hoffman T, Gautreaux S, Wallace D, Roux R, Garey KW. Expansion of clinical pharmacy through increased use of outpatient pharmacists for anticoagulation services. Am J Health Syst Pharm. 2015 Apr 1;72(7):568-72. doi: 10.2146/ajhp140404. PMID: 25788511

Martinson JN, Broadaway S, Lohman E, Johnson C, Alam MJ, Khaleduzzaman M, Garey KW, Schlackman J, Young VB, Santhosh K, Rao K, Lyons RH Jr, Walk ST. Evaluation of portability and cost of a fluorescent PCR ribotyping protocol for Clostridium difficile epidemiology. J Clin Microbiol. 2015 Apr;53(4):1192-7. doi: 10.1128/JCM.03591-14. PMID: 25631804

Garey KW, Aitken SL, Dima-Ala A, Beyda ND, Kuper K, Xie Y, Koo HL. Echinocandin use in hospitalized patients: a multi-institutional study. Am J Med Sci. 2015 Apr;349(4):316-20. doi: 10.1097/MAJ.0000000000000412. PMID: 25607510

Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, Garey KW, Alangaden GJ, Vazquez JA, Groeger JS, Judson MA, Vinagre YM, Heard SO, Zervou FN, Zacharioudakis IM, Kontoyiannis DP, Pappas PG. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis. 2015 Mar 15;60(6):892-9. doi: 10.1093/cid/ciu959. PMID: 25586686

Aitken SL, Hemmige VS, Koo HL, Vuong NN, Lasco TM, Garey KW. Real-world performance of a microarray-based rapid diagnostic for Gram-positive bloodstream infections and potential utility for antimicrobial stewardship. Diagn Microbiol Infect Dis. 2015 Jan;81(1):4-8. doi: 10.1016/j.diagmicrobio.2014.09.025. PMID: 25445120

Bernhardt MB, Moffett BS, Johnson M, Tam VH, Thompson P, Garey KW. Agreement among measurements and estimations of glomerular filtration in children with cancer. Pediatr Blood Cancer. 2015 Jan;62(1):80-4. doi: 10.1002/pbc.25194. PMID: 25263332

Jacobs DM, Beyda ND, Asuphon O, Alam MJ, Garey KW. Host factors and clinical outcomes of Candida colonization in critically ill patients. Mycopathologia. 2015 Feb;179(1-2):87-93. doi: 10.1007/s11046-014-9809-6. PMID: 25173925

 

 

Book Chapters

Aitken SL, Shah DN, Garey KW. Economic burden of Clostridium difficile infection. In: Clostridium difficile: New Challenges for an Old Foe. Tillotson GS, Weiss K (Eds). Future Medicine, London, UK. DOI: 10.2217/EBO.13.185 (2013). ISBN 978-1-78084-315-5

Garey KW. Clostridium difficile infection. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Infectious Diseases. Lenexa, KS: American College of Clinical Pharmacy, 2012

Garey KW and Gerard L. Gastrointestinal infections. In: Helms R, Quan DJ, eds. Textbook of Therapeutics: Drug and Disease Management Eighth Edition. Lippincott, Williams & Wilkins, Inc. April 2006

Sprandel KA, Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases 2nd Edition. New Jersey: Humana Press Aug 2005

Garey KW, Rodvold KA. Drug-Food Interactions. In: Piscitelli SC, Rodvold KA, eds. Drug Interactions in Infectious Diseases. New Jersey: Humana Press Sept 2000

Selected Presentations & Abstracts (since 2010)

Shah DN, Laine ME, Wei W, Smith LC, Palmer HR, Musick WL, Garey KW. Treatment Patterns in Hospitalized Patients with Multiple Clostridium difficile Infection Recurrences and Assessment of Ongoing Use of Pharmacologic Risk Factors. Abstract #1903 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Shah DN, Esquer Z, Ruelas DJ, DuPont HL, Garey KW. Outcome of Patients with Clostridium difficile Infection in a Large Tertiary Care Hospital in Houston. Abstract #2422 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Jacobs DM, Asuphon O, Beyda ND, Alam MJ, Garey KW. Host factors for Candida colonization in critically ill patients. Abstract #2441 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Beyda ND, John J, Alam MJ, Kilic A, Lasco TM, Garey KW. Echinocandin resistant Candida glabrata; risk factors and outcomes in patients with Candidemia. Abstract M-220 (poster walk). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Beyda ND, Shah DN, Lasco T, Koo H, Garey KW. Clinical practice patterns in hospitalized patients at risk for candidemia: implications for rapid Candida species detection methods. Abstract #2488 (poster presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Joseph TB, Shah DN, Palmer HR, Lasco T, DuPont HL, Garey KW. Healthcare resource utilization in patients with recurrent Clostridium difficile infection. Abstract #2154 (oral presentation). 53rd ICAAC, September 10-13, 2013, Denver, CO

Aitken SL, Shah DN, Davis B, Nurshazwani W, Savidge T, DuPont HL, Garey KW. Use of zolpidem, a γ-amino butyric acid receptor agonist, and risk of acquiring Clostridium difficile infection. Abstract #2087 (oral presentation). 53rd ICAAC September 10-13, 2013, Denver, CO

MJ Alam, A Anu, KW Garey. Environmental Investigation of Community Household Contamination of Clostridium difficile. ASM 113th General Meeting. Denver, CO. May 20, 2013

Aitken SL, Alam MJ, Garey KW. Environmental prevalence of Clostridium difficile at a university-affiliated teaching hospital in Houston, Texas. ASM 113th General Meeting. May 20, 2013. Denver, CO

ND Beyda, MJ Alam, KW Garey. Comparison of the T2 Biosystems Candida Assay and Automated Blood Culture in the Detection of Candida species Using Simulated Blood Cultures. ASM 113th General Meeting. May 20, 2013 Denver, CO

Beyda ND, Shah DN, Cottreau J, Salazar M, Frost C, Lasco TM, Garey KW. Aggregate measures of antifungal use in hospitalized patients: Defined daily doses vs. antimicrobial days. IDWeek 2012, October 17-21, 2012, San Diego, CA

Beyda ND, Kilic A, Alam MJ, Lasco TM, Garey KW. Molecular epidemiology and fluconazole susceptibility of Candida glabrata candidemia at a university-affiliated medical center. 52nd ICAAC, September 9-12, 2012, San Francisco, CA

Kilic A, Alam MJ, Tisdel NT, Shah DN, Yapar M, Lasco TM, Garey KW. Development and evaluation of a double multiplex real-time PCR method for simultaneous identification and toxigenic type characterization of C. difficile from stool samples. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Shah DN, Bhatt NS, Chen E, Koo HL, DuPont HL, Garey KW. A risk index based on comorbid conditions and disease severity to predict mortality in patients with Clostridium difficile infection. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Shah DN, Panchumarthi VK, Al-Jashaami LS, Koo HL, DuPont HL, Garey KW. Clinical characteristics of hospitalized patients with community-associated versus non-community-associated Clostridium difficile infection. 52nd ICAAC, San Francisco, CA. September 9-12, 2012.

Kilic A, Alam MJ, Tisdel NT, Shah DN, Yapar M, Lasco TM, Garey KW. Development and evaluation of a double multiplex real-time PCR method for detection of the Clostridium difficile toxin A, toxin B and binary toxin A. Anaerobe 2012, San Francisco, CA. June 27-July 1, 2012

Shah DN, Kilic A, Alam MJ, Darkoh C, De La Cabada J, Jiang ZD, DuPont HL, Garey KW. Characterization of Clostridium difficile strains from patients with mortality attributed to Clostridium difficile infection. Anaerobe 2012, San Francisco, CA. June 27-July 1, 2012.

Garey KW, Shah DN, Habib M, Lasco T. Clinical assessment of nanotechnology and miniaturized magnetic resonance to detect candidemia in hospitalized patients. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Grimes CZ, Shah DN, Koo HL, DuPont HL, Garey KW. Validity of recommended criteria for attributable mortality associated with Clostridium difficile Infection. IDSA 49th Annual Meeting, Boston, MA. October 20-23, 2011.

Shah DN, Dima-ala A, Dolormente K, Arora V, Garey KW. Incidence of antibiotic-associated diarrhea in hospitalized patients given broad spectrum antibiotics. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

Shah DN, Koo HL, Lasco TM, Palmer HR, Garey KW. Assessment of attributable mortality rate of candidemia in candidemia pts with inpatient mortality. 51st ICAAC, Chicago, IL. Sept. 17-20, 2011.

D Shah, R Yau, J Weston, T Lasco, M Salazar, H Palmer, KW Garey. Pre-exposure to antifungals as a risk factor for fluconazole-non-susceptible Candida species in hospitalized patients with candidemia. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

KW Garey, S Ghantoji, D Shah, M Habib, V Arora, ZD Jiang, H DuPont. A randomised, double-blind, placebo-controlled pilot study to assess the effect of rifaximin “chaser” to prevent recurrent diarrhoea in patients with Clostridium difficile infection. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

W Santimaleeworagun, J Christensen, V Singh, DN Shah, KT Chang, VH Tam, and KW Garey. Molecular epidemiology of Clostridium difficile and prevalence of the NAP-1strain among patients admitted to a general and a private hospital in Houston, Texas USA. 21st ECCMID / 27th ICC meeting, Milan, Italy. May 7-10, 2011

Xu R, Salazar M, Weston JS, Shah DN, Putney KS, Garey KW. Susceptibility of Candida species in patients with candidemia. SCCM’s 40th Critical Care Congress, San Diego, CA. January 16-18, 2011.

De La Cabada J, Jiang ZD, Ghantoji SS, Garey KW, Lasco TM, Larocco M, Shah D, DuPont HL. Fecal lactoferrin in Clostridium difficile infection as a predictor of single bouts vs. recurrent disease (Podium presentation). IDSA 48th Annual Meeting, Vancouver, Canada. October 21-24, 2010

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Daptomycin dose-effect relationship against vancomycin-resistant enterococcal bacteremia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Gordon SM, Shah DN, Tran TC, Lasco T, Garey KW. Variations in time to blood culture positivity stratified by Candida species and fluconazole susceptibility. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010. (Oral)

Shah DN, Yau RW, Weston J, Lasco T, Salazar M, Palmer H, Garey KW. Utility of fluconazole as de-escalation therapy in patients with fluconazole-susceptible candidemia. ACCP 2010 Annual Meeting, Austin, TX. October 17-20, 2010.

Tran TC, Palmer HR, Weston JS, Hirsch EB, Shah DN, Cottreau JM, Tam VH, Garey KW. Evaluation of daptomycin PK/PD dose optimization protocol. 50th ICAAC, Boston MA. Sept. 12-15, 2010. (Oral)

Shah DN, Yau RW, Weston J, Xu R, Salazar M, Palmer H, Garey KW. Changes to empiric antifungal therapy based on susceptibility testing results. 50th ICAAC, Boston MA. Sept. 12-15, 2010.

Invited Presentations (since 2012)

Recognizing, treating, and preventing recurrence of Clostridium difficile infection in patients with IBD. 2019 Annual AIBD Conference, Orlando, FL, Dec 14, 2019

Strategies for Prevention and Treatment of Recurrent C. difficile Infection. 2019 ASHP Midyear Clinical Meeting, Las Vegas, NV, Dec 9, 2019

One Health Perspective on Healthcare Acquired Infections. Grand Rounds, University of Tennessee Health Science Center, Memphis TN. Nov 7, 2019

C. difficile infection. Improving provider-patient communication to hasten diagnosis and treatment. Osteopathic Physicians and Surgeons of California Society 30th Annual Fall Conference. Monterey, CA Sept 22, 2019. Encore presentations: Maryland State meeting, Gaithersburg, MD, Oct 6, 2019, and Arizona State meeting, Tucson, AZ, Nov 3, 2019

An integrated curriculum to prepare pharmacy students at the University of Houston. 139th Annual Meeting of the Pharmaceutical Society of Japan. Chiba, Japan. March 20, 2019

Best Practice Update on C. difficile. ASHP Clinical Meeting 2017, Anaheim, CA, Dec 3, 2018.

Group Leader, ID-Week 2018 Poster Board Session: C. difficile. San Francisco, CA, Oct 4, 2018

Early emergence of epidemic Clostridioides difficile ribotype 027 lineages in the US. NIH U01 Systems Biology meeting, La Jolla, CA, Sept 14, 2018

An update on the C. difficile guidelines and fecal microbiota transplantation. ASHP NY Chapter (webinar). May 1, 2018

New updates on C. difficile infection. UTMB Pathology Grand Rounds, Galveston, TX, April 16, 2018

An update on C. difficile Infection: The guidelines have arrived. Oregon Health Science University Grand Rounds, Portland, OR, March 13, 2018

A strawberry-flavored pearl for Clostridium difficile infection. ASHP Clinical Meeting 2017, Orlando, FL, Dec 6, 2017.

Texas-wide Surveillance of Clostridium difficile. Alliance of Professional in Infection Control TX Annual meeting, Temple TX, Oct 9, 2017.

Antibiotic-related Changes in the Microbiome and Clostridium difficile infection. Making a Difference in Infectious Diseases (MAD-ID), Orlando, FL, May 11, 2017

Tips for a Successful Pharmacy Career. West Virginia University Rho Chi Bergy Lecture, Morgantown, WV, April 9, 2017

Translational research involving Clostridium difficile: Blending the host and the bug. Montana State University Frank M. Nelson Distinguished Lecture Series, March 28, 2017

Consequences of recurrent CDI on Patients & Healthcare facilities. 22nd Congress of the European Association of Hospital Pharmacists. Cannes, France, March 23, 2017

Update on C. difficile; New Drugs and new bugs. UT Tyler Health Science Center Grand Rounds, Tyler, Texas, November 18, 2016

Environmental evaluation of C. difficile. APIC Austin Chapter annual meeting. Austin, TX, October 20, 2016

Update on New Antibiotics. New Mexico Society of Health Systems Pharmacists Annual Meeting. October 3, 2016

Antimicrobial stewardship. Vancouver Island Healthcare System Grand Rounds, Victoria, BC, Canada, September 14, 2016

Key Considerations for Improving Patient Outcomes with Antimicrobial Stewardship Programs. Idaho Society of Health Systems Pharmacists Annual meeting. Boise, ID, March 6, 2016. 

Updates in the treatment of C. difficile. ASHP Midyear Clinical Meeting 2015. New Orleans, LA, Dec. 10, 2015. 

Updates in the treatment of C. difficile. ID-Week 2015. San Diego, CA, Oct. 10, 2015. 

Clostridium difficile. Ongoing research and implications for best practice. Texas Department of Healthcare Safety Conference. Bay City, TX, Aug. 21, 2015.

Tips for a successful research career. Temple University School of Pharmacy Research Day. Philadelphia, PA, Feb. 20, 2015.

Management of Invasive Fungal Infections: Applying Evidence-based Strategies and Individualizing Antifungal Therapy. ASHP Midyear, Anaheim, CA, Dec. 10, 2014. 

Antibiotic management – Is it time to think differently with Clostridium difficile? ICAAC Workshop, Washington, DC, Sept. 5, 2014.

New treatment strategies for C. difficile. Anaerobe 2014 Congress. Chicago, IL, July 1, 2014

Update in Infectious Diseases. ASHP Annual Meeting. Las Vegas, NV, June 1, 2014

Update on C. difficile. ASHP Midyear Meeting. Orlando, FL, Dec. 11, 2013

Appropriate dosing of antifungals. Trends in Medical Mycology (TIMM). Copenhagen, Denmark, Oct. 12, 2013

Mentoring pharmacy residents to successful clinical faculty. AACP Annual Meeting. Chicago, IL, July 15, 2013

Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR). European Center for Disease Prevention and Control (ECDC). Stockholm, Sweden, June 17-19, 2013

The Role of Laboratory Testing in Managing Fungal Infections. MAD-ID 2013 Annual Meeting. Orlando, FL, May 11, 2013

What’s the Poop on Clostridium difficile Infection in 2013. MAD-ID 2013 Annual Meeting. Orlando, FL, May 9, 2013

Infectious Diseases Update 2013. APhA Annual Meeting. Los Angeles, CA, March 3, 2013

Clostridium difficile infection: New drugs and new strategies. ASHP Midyear Clinical Meeting, Las Vegas NV, Dec. 4, 2012

Alternative treatments for Clostridium difficile associated diarrhea. ACCP Annual Meeting, Hollywood, FL, Oct. 22, 2012

Surgical Prophylaxis: Dosage Recommendations, Tissue Penetration, and Pharmacokinetic Considerations. 52nd ICAAC. San Francisco, CA, Sept. 10, 2012

Using Antimicrobial Stewardship Programs to Optimize the Use of New Anti-infectives. ASHP Advantage Seminar Series. Presented at the annual meetings of:

Virginia Society of Health Systems Pharmacists, Wintergreen, VA. April 20, 2012
Louisiana Society of Health-Systems Pharmacists, New Orleans, LA. May 26, 2012
Idaho Society of Health-Systems Pharmacists, Sun Valley, ID. Sept. 30, 2012
New Hampshire Society of Health-Systems Pharmacists, Concord, NH. Oct. 8, 2012
Georgia Society of Health-Systems Pharmacists, Young Harris, GA. Oct. 19, 2012

Fidaxomicin and its place in the management of C. difficile infection. Greater New York Hospital Association. Webinar. March 14, 2012

Professional Service & Affiliations

  • American College of Clinical Pharmacy
  • American Society of Health-System Pharmacists
  • Society of Infectious Diseases Pharmacists
  • American Society of Microbiology

Editorial Appointments

  • Associate Editor, Annals of Pharmacotherapy
  • Editorial Board Chair, Annals of Pharmacotherapy
  • Reviewer, Infection Control and Hospital Epidemiology, Annals of Pharmacotherapy, American Journal of Health System Pharmacy, American Journal of Preventive Medicine, Medical Principles and Practice, Pharmacotherapy, The Journal of Pharmacy Practice and Research, Therapeutics and Clinical Risk Management, Future Drugs, Journal of Antimicrobial Chemotherapy, BMC Infectious Diseases, Journal of Infection, American Journal of Tropical Medicine & Hygiene, Lancet, Medical Mycology, Clinical Infectious Diseases, Diagnostic Microbiology and Infectious Diseases, Digestive Diseases and Sciences, Critical Care, Archives of Internal Medicine, Scandinavian Journal of Infectious Diseases, Clinical Microbiology and Infection, Nature Reviews Gastroenterology and Hepatology, International Journal of Immunogenetics, Canadian Medical Association Journal